A premier biopharma innovator transforming neuropsychiatric care with a robust pipeline of FDA-approved therapies targeting Alzheimer's, Parkinson's, and addiction disorders.
Neurocrine offers compelling growth potential with a diversified product portfolio addressing unmet needs in high-value neuropsychiatric markets where competition remains limited; Strong balance sheet with $713M cash provides flexibility for R&D investment and strategic M&A opportunities to extend market leadership; Consistent revenue growth trajectory from $1.49B to $2.86B over four years validates commercial scalability.
High valuation multiples may not be fully justified given the inherent regulatory risks and long development cycles typical of CNS therapeutics; Significant operating expense burden with general and administrative costs reaching $1.16B could compress margins if sales growth slows; Dependence on a few blockbuster drugs creates concentration risk as patent cliffs approach for legacy products.
Neurocrine Biosciences Inc is a leading biopharmaceutical company specializing in developing and commercializing proprietary treatments for neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and addiction. The company serves patients in the United States through its innovative portfolio of small molecule drugs and biologics that target specific neurotransmitter systems. Key products include branded medications such as Xyrem for narcolepsy and Abilify for schizophrenia, with significant growth driven by recent approvals in neurodegenerative markets.
The company demonstrated exceptional financial strength with record net income of $478.6M in 2025, up from $341.3M the prior year, reflecting robust commercial execution and pipeline progress. Operating cash flow surged to $782.7M while total assets expanded to $4.63B, indicating healthy capital generation despite significant investing outflows of $264.4M likely tied to strategic acquisitions or asset builds.
The global neuropsychiatric drug market is experiencing rapid expansion driven by aging demographics, increased diagnostic awareness, and technological advancements in CNS target identification. Biopharmaceutical companies are increasingly focusing on differentiated mechanisms of action to overcome the limitations of current standard-of-care therapies in Alzheimer's and Parkinson's disease.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.49B | $1.89B | $2.36B | $2.86B |
| Cost of Revenue | $23.2M | $39.7M | $34.0M | $52.1M |
| Gross Profit | $1.47B | $1.85B | $2.32B | $2.81B |
| Operating Expenses | $1.22B | $1.60B | $1.75B | $2.19B |
| Operating Income | $249.0M | $250.9M | $570.5M | $619.1M |
| G&A | $752.7M | $887.6M | $1.01B | $1.16B |
| Stock-Based Comp | $173.1M | $194.3M | $195.5M | $217.9M |
| Depreciation | $15.1M | $17.8M | $23.5M | $26.0M |
| Amortization | $500.0K | $3.5M | $3.6M | $4.1M |
| Other OpEx | $463.8M | $708.9M | $743.6M | $1.03B |
| Non-Operating Income | $-35.1M | $81.2M | $-84.5M | $86.3M |
| Interest Expense | $7.1M | $4.6M | — | — |
| Pre-Tax Income | $213.9M | $332.1M | $486.0M | $705.4M |
| Income Tax | $59.4M | $82.4M | $144.7M | $226.8M |
| Continuing Ops | $154.5M | $249.7M | $341.3M | $478.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $154.5M | $249.7M | $341.3M | $478.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $154.5M | $249.7M | $341.3M | $478.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.45B | $1.61B | $1.72B | $2.52B |
| Cash & Equivalents | $262.9M | $251.1M | $233.0M | $713.0M |
| Accounts Receivable | $350.0M | — | $479.1M | $686.8M |
| Inventory | $35.1M | $38.3M | $57.4M | $69.0M |
| Other Current Assets | $805.5M | $1.32B | $955.2M | $1.05B |
| Long-Term Assets | $915.2M | $1.64B | $1.99B | $2.11B |
| PP&E (Net) | $58.6M | $70.8M | $82.6M | $89.8M |
| Intangibles | $37.2M | $35.5M | $36.5M | — |
| Goodwill | $5.4M | $5.8M | $5.7M | — |
| Operating Leases | $87.0M | $276.5M | $509.4M | $455.4M |
| LT Securities | $299.4M | — | — | — |
| Other LT Assets | $427.6M | $1.26B | $1.36B | $1.56B |
| Total Assets | $2.37B | $3.25B | $3.72B | $4.63B |
| Current Liabilities | $537.7M | $654.8M | $507.7M | $743.4M |
| Current Leases | $17.4M | $32.0M | $40.6M | $56.0M |
| Taxes Payable | — | $24.4M | — | $68.0M |
| Other Current Liab | $520.3M | $598.4M | $467.1M | $619.4M |
| Long-Term Liabilities | $123.2M | $364.6M | $621.3M | $635.0M |
| LT Operating Leases | $93.5M | $258.3M | $455.1M | $415.3M |
| Other LT Liab | $29.7M | $10.3M | $5.5M | $5.2M |
| Total Liabilities | $660.9M | $1.02B | $1.13B | $1.38B |
| Shareholders' Equity | $1.71B | $2.23B | $2.59B | $3.25B |
| Retained Earnings | $-406.8M | $-157.1M | $29.2M | $447.7M |
| AOCI | $-7.9M | $7.0M | $5.8M | $13.1M |
| Total L&E | $2.37B | $3.25B | $3.72B | $4.63B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $154.5M | $249.7M | $341.3M | $478.6M |
| Non-Cash Adjustments | $-111.7M | $39.8M | $176.9M | $-107.5M |
| Working Capital Changes | $296.6M | $100.4M | $77.2M | $411.6M |
| Cash from Operations | $339.4M | $389.9M | $595.4M | $782.7M |
| Capital Expenditures | $16.5M | $28.3M | $38.2M | $34.0M |
| Cash from Investing | $-177.1M | $-467.1M | $-126.8M | $-264.4M |
| Share Buybacks | — | — | $300.0M | $167.7M |
| Cash from Financing | $-234.3M | $65.3M | $-486.7M | $-38.3M |
| FX Effect | $-1.3M | $300.0K | $0 | $0 |
| Net Change in Cash | $-73.3M | $-11.6M | $-18.1M | $480.0M |
| Beginning Cash | $344.0M | $270.7M | $259.1M | $241.0M |
| Ending Cash | $270.7M | $259.1M | $241.0M | $721.0M |
Commercial sales of branded small molecule drugs and biologics for neuropsychiatric indications; Strategic licensing and collaboration agreements with major pharmaceutical partners; Research and development activities focused on novel mechanisms of action in the CNS.
Prolonged development timelines and high failure rates associated with complex CNS target validation; Potential loss of exclusivity on key patents leading to generic competition impacting revenue streams; Regulatory uncertainties regarding accelerated approval pathways and evolving pricing reimbursement policies for orphan drugs.
Proprietary intellectual property portfolio providing strong patent protection across its core drug candidates; Deep scientific expertise in neurodegenerative disease biology enabling first-in-class or best-in-class product differentiation; Established commercial infrastructure with a proven track record of successful FDA approvals and market access strategies.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.